ONCS stock is moving higher in early trading on July 13, 2020, after the company was featured on an NBC Television broadcast in Portland.
OncoSec Medical Incorporated (NASDAQ:ONCS), a company developing late-stage intratumoral DNA–based cancer immunotherapies, today announced the promising potential of its novel DNA–encodable vaccine candidate, CORVax12, which is designed to act as a prophylactic vaccine to prevent COVID-19, was featured in the show ‘Straight Talk’ by KGW NewsChannel 8, an NBC TV affiliate in Portland, Oregon.
You can watch the full episode and read the article here: https://www.kgw.com/article/entertainment/television/programs/straight-talk/providence-researchers-developing-unique-covid-19-vaccine/283-9c091f9d-3379-4252-9c30-e2f7447827b1
OncoSec and researchers at Providence Cancer Institute previously announced a collaboration to conduct a first-in-human trial of OncoSec’s CORVax12 vaccine candidate. Providence has filed an Investigator-Initiated Investigational New Drug (IND) Application with the United States Food and Drug Administration (FDA) and plans to initiate a phase 1 vaccine trial of healthy adult volunteers upon FDA clearance.
CORVax12 consists of OncoSec’s existing product candidate, TAVO™ (interleukin-12 or “IL-12” plasmid), in combination with an immunogenic component of the SARS-CoV-2 virus recently developed by researchers at NIH’s National Institute of Allergy and Infectious Diseases (“NIAID”) and licensed to OncoSec on a non-exclusive basis. Specifically, OncoSec’s CORVax12 vaccine approach combines the co-administration of TAVO with a DNA-encodable version of the SARS-CoV-2 spike or “S” glycoprotein to enhance immunogenicity of the component developed by scientists at the NIAID Vaccine Research Center. CORVax12 is designed to drive a coordinated vaccine response, capable of drawing upon the innate, adaptive humoral, and adaptive cellular arms. Researchers believe this multi-pronged innate, adaptive and cellular immune response is likely to be important in generating a robust anti-viral response.
On June 29, 2020, OncoSec Medical announced that the Company joined the Russell Microcap® Index.
Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
“Inclusion in the Russell Microcap Index underscores the progress we are making to increase shareholder value by driving our two KEYNOTE clinical programs forward, including our pivotal KEYNOTE-695 study in metastatic melanoma,” said Daniel J. O’Connor, President and CEO at OncoSec. “Inclusion in the Index significantly benefits our Company and shareholders by elevating our visibility within the global investment community during what is poised to be a breakout year for OncoSec. We look forward to completing enrollment in KEYNOTE-695 and expect to provide an interim data update at an upcoming medical meeting.”
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.